(Q38036150)

27 August 2017

title

Pharmacogenomics of adverse drug reactions: implementing personalized medicine (English)

1 reference

27 August 2017

1 reference

personalized medicine

1 reference

3

Yuan-Tsong Chen

1 reference

27 August 2017

Chun-Yu Wei

1

1 reference

27 August 2017

Ming-Ta Michael Lee

series ordinal

2

1 reference

27 August 2017

publication date

19 August 2012

1 reference

27 August 2017

published in

Human Molecular Genetics

1 reference

27 August 2017

volume

21

1 reference

27 August 2017

issue

R1

1 reference

27 August 2017

page(s)

R58-65

1 reference

Pharmacogenomics: translating functional genomics into rational therapeutics

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Pharmacogenetics - five decades of therapeutic lessons from genetic diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Pharmacogenetics and pharmacogenomics: role of mutational analysis in anti-cancer targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Adverse drug reactions: role of pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Priorities and standards in pharmacogenetic research

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Genetic susceptibility to adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Pharmacogenomics and individualized drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Bleeding Complications to Long-Term Oral Anticoagulant Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Pharmacogenetics of warfarin elimination and its clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Estimation of the warfarin dose with clinical and pharmacogenetic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Screening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that's the question

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Membrane transporters in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Achieving greater reductions in cardiovascular risk: lessons from statin therapy on risk measures and risk reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

SLCO1B1 variants and statin-induced myopathy--a genomewide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Pharmacogenomics of human OATP transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

The SLCO1B1*5 genetic variant is associated with statin-induced side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

The human leucocyte antigen-DRB1*1302-DQB1*0609-DPB1*0201 haplotype may be a strong genetic marker for aspirin-induced urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Genetic mechanism of aspirin-induced urticaria/angioedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

How TCRs bind MHCs, peptides, and coreceptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Penicilloyl peptides are recognized as T cell antigenic determinants in penicillin allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Pharmacological interaction of drugs with immune receptors: the p-i concept.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

HLA-B*1502-bound peptides: implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Pharmacogenetic study of statin therapy and cholesterol reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Pharmacogenetics of apolipoprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

APOE gene polymorphisms and response to statin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

21 January 2018

Statins personalized.

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Delayed hypersensitivity to aminopenicillins is related to major histocompatibility complex genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Medical genetics: a marker for Stevens-Johnson syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

HLA-B*5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

Warfarin and the Inhibition of Vitamin K Activity by an Oxide Metabolite

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDS341

21 January 2018

Identifiers

DOI

10.1093/HMG/DDS341

1 reference

27 August 2017

1 reference